Compare RYTM & IDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | IDCC |
|---|---|---|
| Founded | 2008 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.6B |
| IPO Year | 2017 | 2007 |
| Metric | RYTM | IDCC |
|---|---|---|
| Price | $93.66 | $286.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | $131.14 | ★ $412.50 |
| AVG Volume (30 Days) | ★ 555.5K | 331.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.79% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | ★ $307,404,000.00 |
| Revenue This Year | $55.34 | N/A |
| Revenue Next Year | $86.06 | $3.38 |
| P/E Ratio | ★ N/A | $134.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.99 | $213.06 |
| 52 Week High | $122.20 | $412.60 |
| Indicator | RYTM | IDCC |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 58.27 |
| Support Level | $82.43 | $249.31 |
| Resistance Level | $100.69 | $365.98 |
| Average True Range (ATR) | 4.46 | 10.57 |
| MACD | 0.64 | 6.17 |
| Stochastic Oscillator | 81.49 | 75.76 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.